BIO-TECHNE Corp
TECHAPI behind this page
TECH FY 2025 request
Playground key active
/api/financials?ticker=TECH&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 1,219,635 | 1,159,060 | +5.2% |
Show Product Lines breakouts |
|||
| Consumables | 972,286 | 928,180 | +4.8% |
| Consumables · All Other Segments | 4,152 | 4,153 | -0.0% |
| Consumables · Diagnostics and Spatial Biology | 283,969 | 266,348 | +6.6% |
| Consumables · Operating Segments | 972,286 | 928,180 | +4.8% |
| Consumables · Protein Sciences | 684,165 | 657,679 | +4.0% |
| Instruments | 112,086 | 108,270 | +3.5% |
| Product and Services | 1,195,942 | 1,135,715 | +5.3% |
| Royalty | 23,693 | 23,345 | +1.5% |
| Service | 111,570 | 99,265 | +12.4% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 346,263 | 326,392 | +6.1% |
| Protein Sciences · Operating Segments | 870,245 | 830,902 | +4.7% |
Show Geography breakouts |
|||
| APAC, excluding Greater China | 77,263 | 73,904 | +4.5% |
| CN | 100,463 | 99,467 | +1.0% |
| EMEA, excluding United Kingdom | 266,305 | 241,432 | +10.3% |
| GB | 54,827 | 50,012 | +9.6% |
| Rest of World | 37,547 | 36,498 | +2.9% |
| US | 683,230 | 657,747 | +3.9% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -1,025 | -2,387 | +57.1% |
| Operating Segments | 1,216,508 | 1,157,294 | +5.1% |
| Cost of Revenue | 429,363 | 389,335 | +10.3% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 147,946 | 134,963 | +9.6% |
| Protein Sciences · Operating Segments | 212,225 | 201,981 | +5.1% |
| Gross Profit | 790,272 | 769,725 | +2.7% |
| Selling, General & Administrative | 588,521 | 466,375 | +26.2% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 136,103 | 127,131 | +7.1% |
| Protein Sciences · Operating Segments | 229,058 | 217,235 | +5.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 8,088 | 9,142 | -11.5% |
| Research And Development Expense Excluding Acquired In Process Cost | 99,496 | 96,664 | +2.9% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 40,890 | 39,752 | +2.9% |
| Protein Sciences · Operating Segments | 58,609 | 56,911 | +3.0% |
| Operating Expenses | 688,017 | 563,039 | +22.2% |
| Operating Income | 102,255 | 206,686 | -50.5% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 21,324 | 24,546 | -13.1% |
| Protein Sciences · Operating Segments | 370,353 | 354,775 | +4.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 391,677 | 379,321 | +3.3% |
| Interest Expense | -8,509 | -15,736 | +45.9% |
| Investment Income Interest And Dividend | 3,886 | 3,323 | +16.9% |
| Other Non-Operating Income (Expense) | 831 | -8,584 | +109.7% |
| Non-Operating Income (Expense) | -3,792 | -20,997 | +81.9% |
| Income Before Taxes | 98,463 | 185,689 | -47.0% |
| Income Tax Expense (Benefit) | 25,063 | 17,584 | +42.5% |
| Net Income | 73,400 | 168,105 | -56.3% |
Show Equity Components breakouts |
|||
| Retained Earnings | 73,400 | 168,105 | -56.3% |
| Net Income | 73,400 | 168,105 | -56.3% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 24,002 | -7,492 | +420.4% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | -5,566 | -4,760 | -16.9% |
| Other Comprehensive Income Loss Net Of Tax | 18,436 | -12,252 | +250.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 18,436 | — | — |
| Other Comprehensive Income | 18,436 | -12,252 | +250.5% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | -5,566 | -4,760 | -16.9% |
| Accumulated Other Comprehensive Income | 18,436 | -12,252 | +250.5% |
| Accumulated Translation Adjustment | 24,002 | -7,492 | +420.4% |
| Comprehensive Income | 91,836 | 155,853 | -41.1% |
| EPS (Basic) | 0.47 | 1.07 | -56.1% |
| EPS (Diluted) | 0.46 | 1.05 | -56.2% |
| Wtd Avg Shares (Basic) | 157,521 | 157,708 | -0.1% |
| Wtd Avg Shares (Diluted) | 159,717 | 160,774 | -0.7% |
| Revenue | 1,219,635 | 1,159,060 | +5.2% |
| Income Loss From Equity Method Investments | 938 | -6,841 | +113.7% |
| Net Income Loss Available To Common Stockholders Basic | 73,363 | 168,072 | -56.4% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 162,186 | 151,791 | +6.8% |
| Accounts Receivable | 206,876 | 241,394 | -14.3% |
| Inventory | 189,446 | 179,731 | +5.4% |
| Assets Of Disposal Group Including Discontinued Operation Current | 12,332 | 9,773 | +26.2% |
| Other Assets Current | 37,460 | 33,658 | +11.3% |
| Total Current Assets | 608,300 | 617,419 | -1.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 245,719 | 251,154 | -2.2% |
| Operating Lease Right-of-Use Assets | 73,399 | 91,285 | -19.6% |
| Goodwill | 980,935 | 972,663 | +0.9% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology | 554,159 | 549,214 | +0.9% |
| Protein Sciences | 426,776 | 423,449 | +0.8% |
Show Business Acquisition breakouts |
|||
| Lunaphore Technologies SA. | 104,650 | — | — |
| Deferred Tax Assets | 10,307 | — | — |
| Other Non-Current Assets | 273,609 | 264,265 | +3.5% |
| Total Assets | 2,557,868 | 2,703,867 | -5.4% |
| Intangible Assets | 365,599 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 365,599 | 507,081 | -27.9% |
Show Geography breakouts |
|||
| Europe | 63,628 | 63,138 | +0.8% |
| United States and Canada | 301,971 | 443,740 | -31.9% |
| Current Liabilities | |||
| Accounts Payable | 25,311 | 37,968 | -33.3% |
| Employee Related Liabilities Current | 65,791 | 49,818 | +32.1% |
| Accrued Liabilities | 25,663 | 24,886 | +3.1% |
| Deferred Revenue (Current) | 32,571 | 27,930 | +16.6% |
| Accrued Income Taxes Current | 10,770 | 3,706 | +190.6% |
| Operating Lease Liability Current | 14,098 | 12,920 | +9.1% |
| Other Liabilities Current | 1,645 | 2,151 | -23.5% |
| Total Current Liabilities | 175,849 | 159,379 | +10.3% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 6,169 | 55,863 | -89.0% |
| Operating Lease Liabilities | 83,960 | 87,618 | -4.2% |
| Other Non-Current Liabilities | 27,082 | 13,157 | +105.8% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 346,000 | 319,000 | +8.5% |
| Stockholders' Equity | |||
| Common Stock | 1,550 | 1,582 | -2.0% |
| Additional Paid In Capital Common Stock | 911,089 | 820,337 | +11.1% |
| Retained Earnings | 1,066,049 | 1,325,247 | -19.6% |
| Accumulated Other Comprehensive Income | -59,880 | -78,316 | +23.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1,918,808 | 2,068,850 | -7.3% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | 2,536 | 8,102 | -68.7% |
| Accumulated Other Comprehensive Income | -59,880 | -78,316 | +23.5% |
| Accumulated Translation Adjustment | -62,416 | -86,418 | +27.8% |
| Additional Paid In Capital | 911,089 | 820,337 | +11.1% |
| Common Stock | 1,550 | 1,582 | -2.0% |
| Retained Earnings | 1,066,049 | 1,325,247 | -19.6% |
| Total Liabilities & Equity | 2,557,868 | 2,703,867 | -5.4% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 109,903 | 111,711 | -1.6% |
| Fair Value Write Up Of Acquired Inventory | 751 | 729 | +3.0% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 751 | 729 | +3.0% |
| Deferred Income Taxes And Tax Credits | -51,107 | -39,447 | -29.6% |
| Stock-Based Compensation | 40,833 | 38,042 | +7.3% |
| Equity Method Investment Realized Gain Loss On Disposal | -938 | 6,841 | -113.7% |
| Asset Impairment Restructuring Charge | 21,312 | 2,634 | +709.1% |
| Noncash Portion Of Lease Expense | 685 | 1,708 | -59.9% |
| Impairment Of Long Lived Assets To Be Disposed Of | 80,503 | 21,963 | +266.5% |
| Other Operating Activities Cash Flow Statement | 675 | 301 | +124.3% |
| Increase Decrease In Accounts And Other Receivables | 34,132 | -20,533 | +266.2% |
| Change in Inventory | -18,144 | -14,215 | -27.6% |
| Increase Decrease In Prepaid Expense | -14,372 | -3,146 | -356.8% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -13,954 | 25,769 | -154.2% |
| Increase Decrease In Employee Related Liabilities | 15,408 | 12,618 | +22.1% |
| Increase Decrease In Accrued Income Taxes Payable | 8,469 | -10,599 | +179.9% |
| Net Cash from Operations | 287,556 | 298,981 | -3.8% |
| Deferred Income Taxes | -51,152 | -40,161 | -27.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 0.8 | 2.5 | -68.0% |
| Investing Activities | |||
| Proceeds From Sale Of Available For Sale Securities Debt | 1,085 | 28,083 | -96.1% |
| Capital Expenditures | -31,006 | -62,877 | +50.7% |
| Proceeds Payments From Equity Method Investment Dividends Or Distributions Return Of Capital | 7,291 | 6,997 | +4.2% |
| Payments To Acquire Equity Securities Fv Ni | -15,000 | — | — |
| Proceeds From Sale Of Property Held For Sale | 2,447 | — | — |
| Net Cash from Investing | -35,183 | -203,030 | +82.7% |
| Financing Activities | |||
| Payments Of Dividends Common Stock | -50,391 | -50,419 | +0.1% |
| Proceeds From Stock Options Exercised | 51,739 | 60,935 | -15.1% |
| Share Repurchases | -275,731 | -80,042 | -244.5% |
| Proceeds From Long Term Lines Of Credit | 104,000 | 225,000 | -53.8% |
| Repayments Of Lines Of Credit | -77,000 | -256,000 | +69.9% |
| Tax Withholding for Share Compensation | -6,522 | -21,872 | +70.2% |
| Net Cash from Financing | -253,905 | -122,398 | -107.4% |
| Supplemental | |||
| Income Taxes Paid | 74,357 | 65,254 | +14.0% |
| Interest Paid | 18,955 | 14,502 | +30.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 11,927 | -2,333 | +611.2% |
| Net Change in Cash | 10,395 | -28,780 | +136.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 162,186 | 151,791 | +6.8% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.